Intellia Resumes Key Trial and Expands ATM Program

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.

On March 2, 2026, Intellia Therapeutics, Inc. amended its at-the-market equity offering agreement with Jefferies LLC, raising the total program size from $750 million to about $1.04 billion and filing a new prospectus supplement to cover up to $400 million in additional shares, including unsold capacity. As of that date, the company had already sold roughly $635.3 million of common stock under the program, reinforcing its financial flexibility while maintaining Jefferies as sales agent on a best-efforts basis with up to 3% compensation on gross proceeds.

Also on March 2, 2026, Intellia disclosed that the U.S. Food and Drug Administration lifted the clinical hold imposed on October 29, 2025, on its MAGNITUDE Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy and aligned on safety-focused mitigation measures for both MAGNITUDE and MAGNITUDE-2. The company is now working with investigators, ethics committees and international regulators to resume enrollment in these pivotal trials, a move that restores momentum to a key late-stage gene-editing program in a high-need cardiovascular and neurological indication.

The most recent analyst rating on (NTLA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Spark’s Take on NTLA Stock

According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.

The score is held back primarily by weak financial performance (persistent losses, cash burn, and volatile revenue) and limited valuation support due to negative earnings. These are partly offset by improving technical momentum and an earnings-call setup that highlights a potentially pivotal HAE readout and commercialization path, though the unresolved FDA hold and safety uncertainty in the ATTR program remains a major risk.

To see Spark’s full report on NTLA stock, click here.

More about Intellia Therapeutics

Intellia Therapeutics, Inc. is a biotechnology company focused on developing CRISPR-based genome editing therapies, with a particular emphasis on treatments for genetic diseases such as transthyretin amyloidosis. The company advances its investigational candidates through late-stage clinical trials and accesses capital markets to fund research, development and potential commercialization activities.

Operating in the competitive gene-editing and rare disease space, Intellia targets patients with high unmet medical need, including those with cardiomyopathy and polyneuropathy linked to transthyretin amyloidosis. Its collaborations with financial institutions and regulators, along with its clinical programs, are central to its strategy to secure funding and advance therapies toward approval.

Average Trading Volume: 4,571,737

Technical Sentiment Signal: Hold

Current Market Cap: $1.63B

Learn more about NTLA stock on TipRanks’ Stock Analysis page.